Study finds no beta-cell benefits with canakinumab, anakinra

04/17/2013 | Healio

Neither canakinumab nor anakinra fared better than placebo in delaying beta-cell dysfunction in patients with new-onset type 1 diabetes, a study in The Lancet found. Researchers also noted a greater prevalence of adverse events in patients who took anakinra compared with those in the placebo group.

View Full Article in:

Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA